

# Children's Mercy HOSPITALS & CLINICS



RESEARCH ADMINISTRATION  
2401 Gillham Road  
Kansas City, Missouri 64108

[www.childrens-mercy.org](http://www.childrens-mercy.org)

2567 '02 JUL -2 P1:35

June 27, 2002

## Office of Medical Research

Ralph E. Kauffman, MD  
Marion Merrell Dow / Missouri Chair  
Director, Medical Research  
Professor, Pediatrics and Pharmacology  
E-mail: [rkauffman@cmh.edu](mailto:rkauffman@cmh.edu)

Stephen D. Simon, PhD  
Research Biostatistician, Medical Research  
E-mail: [ssimon@cmh.edu](mailto:ssimon@cmh.edu)

Linda Storm  
AA to Dr. Kauffman  
E-mail: [lstorm@cmh.edu](mailto:lstorm@cmh.edu)  
Phone: (816) 234-3961  
Fax: (816) 855-1703

## Research and Grants Administration

William H. Caskey, PhD  
Director, Research and Grants  
Administration  
Associate Professor of Medicine  
E-mail: [wcaskey@cmh.edu](mailto:wcaskey@cmh.edu)

Patricia Eshleman  
Director, Clinical Trials Administration  
E-mail: [teshleman@cmh.edu](mailto:teshleman@cmh.edu)

Donna Mattingly  
IRB Coordinator and Grants Specialist  
E-mail: [dmattingly@cmh.edu](mailto:dmattingly@cmh.edu)

Kathy Johnson, RN, CCRC  
Manager, Research Compliance  
E-mail: [kjohnson@cmh.edu](mailto:kjohnson@cmh.edu)

Linda Foland  
Contracts Specialist  
Clinical Trials Administration  
E-mail: [lfoland@cmh.edu](mailto:lfoland@cmh.edu)

Stephanie Huff, MA  
Grant Specialist  
E-mail: [sfarley@cmh.edu](mailto:sfarley@cmh.edu)

Kelly Evans  
Data Specialist  
E-mail: [kmevans@cmh.edu](mailto:kmevans@cmh.edu)

Stephanie Ford, Administrative Assistant  
E-mail: [sford@cmh.edu](mailto:sford@cmh.edu)  
Phone: (816) 234-3879  
Fax: (816) 855-1982

## Central Clinical Research Coordinators

Mary Valla Crook, RN, BSN, CCRC  
Advanced Clinical Research Coordinator  
E-mail: [mcrook@cmh.edu](mailto:mcrook@cmh.edu)

Candy Schmoll, RN, BSN, CCRC  
Clinical Research Coordinator  
E-mail: [cschmoll@cmh.edu](mailto:cschmoll@cmh.edu)

Dockets Management Branch  
(HFA-305)  
Food and Drug Administration  
5630 Fishers Lane - Room 1061  
Rockville, MD 20652

Docket Number: 02N-0152

Dear Sir or Madam:

As pediatric health professionals and investigators with a long history of working to improve pediatric therapeutics, we welcome the opportunity to comment on the relationship between the 1998 Pediatric Rule and the Best Pharmaceuticals for Children Act (P.L. 107-109). Securing safe and appropriate drugs for use by children has had a long and laborious history. However, significant progress toward pediatric drug studies and labeling has been made over the last five years due to regulatory and legislative initiatives on behalf of children.

A dual approach to obtaining essential pediatric data was instituted in the late 1990's. This approach combines: 1) incentives for voluntary studies of drug safety and dosing by industry (extended in January 2002 in the Best Pharmaceuticals for Children Act [BPCA]); and 2) a regulation requiring pediatric studies of new drugs and some already marketed drugs, known as the Pediatric Rule.

In March 2002 the FDA proposed to suspend the Pediatric Rule. While this proposal was reversed following widespread protest, this action indicates that children are at risk of losing the ground we have fought so hard to secure for them.

The Pediatric Rule ensures that children are no longer a therapeutic afterthought by the pharmaceutical industry. It is an essential and successful tool in ensuring that children have the quality and quantity of drugs they need. All new drugs must be studied for pediatric use at the time a drug comes to market unless the FDA grants a waiver. This makes medications for children a certainty, not an option and puts children on a level playing field with adults for the first time.

**02N-0152** **C11**  
We believe that all components of the 1998 Pediatric Rule must be preserved. It is a comprehensive approach to securing pediatric studies.

FDA has not yet invoked all the provisions of the Pediatric Rule; however, together they weave a safety net for children to ensure that children have appropriate drugs available for their use.

The following comments and recommendations respond to questions and issues raised in the Federal Register notice soliciting public comments:

- Retiring or relaxing any authorities currently in the Pediatric Rule is inappropriate and would be to the detriment of children. It must always be kept in mind that BPCA is time-limited, voluntary and subject to continuation by the Congress. Those facts speak directly to the need to ensure that the Pediatric Rule remains in place in its entirety.
- Noting again that the BPCA is subject to continuation by Congress and that future reauthorization is uncertain, the FDA should make it clear that the Pediatric Rule applies to all labeled and potential indications as well as new indications. Thus, if a company submits a supplemental indication to the FDA, it invokes the Pediatric Rule. It is important that appropriate pediatric studies be conducted for that new use; and if the current label lacks appropriate pediatric use information (e.g., for neonates) the FDA should also include in their requirement for pediatric studies of the new indication, any pediatric studies that may be needed for the currently labeled or potential pediatric indications.
- In determining the process of when pediatric studies are conducted, the FDA should adopt the detailed process for requesting pediatric studies of already marketed drugs and securing labeling that is outlined in the BPCA.
- It is essential that the Pediatric Rule remain in place because it is the only mechanism that ensures that biological products will be studied and available for children. No provision of BPCA applies specifically to biological products since the legislation focuses on drugs covered by the Food, Drug and Cosmetic Act (FDCA) and the vast majority of biologics are covered under the Public Health Service Act. Moreover, some of the most innovative new therapies now and in the future are biological products, which are not covered under BPCA.
- Appropriate formulations are an essential component of providing medications for the pediatric population. It is a requisite for studies in infants and younger children to develop age appropriate formulations, if necessary. Failure to require needed formulations for specific age populations negates the intent of the BPCA and the Pediatric Rule.
- BPCA limits its reference to "recommendation" for formulation changes only to studies completed under public contract. This provision was included to acknowledge

that once a formulation is developed in the study phase, while it may be necessary to manufacture that formulation, it may not always be possible to scale up the formulation for distribution to the general public. The Rule is necessary to ensure that pediatric formulations are developed where appropriate and necessary.

Thank you for your consideration of these comments.

Sincerely,



Gregory L. Kearns, Pharm. D., FCP  
Marion Merrell Dow, Missouri Chair  
in Pediatric Pharmacology  
Professor, Pediatrics and Pharmacology



Ralph E. Kauffman, M.D., FAAP  
Marion Merrell Dow/Missouri Chair  
in Medical Research  
Professor, Pediatrics and Pharmacology



2401 Gillham Road  
Kansas City, Missouri 64108

Dockets Management Branch  
(HFA-305)  
Food and Drug Administration  
5630 Fishers Lane - Room 1061  
Rockville, MD 20652



45 FCATAMP 20652

